We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

This study is currently recruiting participants.
Verified July 2017 by Celgene
Sponsor:
ClinicalTrials.gov Identifier:
NCT02955550
First Posted: November 4, 2016
Last Update Posted: July 24, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Celgene
  Purpose

This study will find the highest acceptable treatment dose and timing of infusion of cord blood, culture expanded natural killer (NK) cells, a kind of immune cell, in patients with multiple myeloma.

The NK cells will be given at varying days post autologous stem cell transplant. rhIL-2 is administered after treatment to help the NK cells expand in the body. The safety of this treatment will be studied and researchers want to learn if NK cells will help in treating multiple myeloma.


Condition Intervention Phase
Multiple Myeloma Drug: rhIL-2 Biological: PNK-007 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Multicenter, Open-label, Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion Following Autologous Stem Cell Transplant for Multiple Myeloma

Resource links provided by NLM:


Further study details as provided by Celgene:

Primary Outcome Measures:
  • Dose-Limiting Toxicity (DLT) [ Time Frame: Up to 28 days ]
    Number and severity of adverse events within 28 days of administration

  • Maximum Tolerated Dose (MTD) [ Time Frame: Up to 28 days ]
    The maximum dose safely administered for the treatment of patients with multiple myeloma

  • Dose Timing After Autologous Stem Cell Transplant [ Time Frame: Up to 28 days ]
    The optimal dose timing safely administered for the treatment of patients with multiple myeloma post ASCT

  • Adverse Events (AEs) [ Time Frame: Up to 12 months ]
    Number and severity of adverse events within 12 months of administration


Secondary Outcome Measures:
  • Response Rate [ Time Frame: Up to day 100 ]
    Clinical efficacy at day 90-100 post ASCT per International Myeloma Working Group criteria, including minimal residual disease


Estimated Enrollment: 40
Actual Study Start Date: January 19, 2017
Estimated Study Completion Date: November 30, 2018
Estimated Primary Completion Date: November 30, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PNK-007 and rhIL-2
Melphalan per institutional practices (within Day -5 to 01), ASCT (Day 0), PNK-007 at varying dose levels (within Day 2 to Day 14) and rhIL-2 every other day starting day of PNK-007 administration.
Drug: rhIL-2
Human recombinant Interleukin-2
Biological: PNK-007
PNK-007 is a culture-expanded cell population derived from human cord blood hematopoietic stem/progenitor cells.

Detailed Description:

The primary objective of the study is to assess safety and determine the maximum tolerated dose of PNK-007 as well as the feasibility of treating at various timepoints following ASCT in subjects with multiple myeloma. The secondary objective is to explore the potential clinical efficacy by day 90-100 post ASCT.

Treatment plan includes ASCT followed by PNK-007 which will be administered IV Day 14 post ASCT to determine the maximum tolerated dose. Once the IV Day 14 post ASCT. PNK-007 will be followed by up to six rhIL-2 injections to support the NK cells expansion in the body.

Subjects will be followed for up to 12 months post PNK-007.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Subjects must satisfy the following criteria to be enrolled in the study:

  1. Subject has eligible disease status:

    1. Newly diagnosed and are undergoing induction therapy prior to undergoing first Autologous stem cell transplant (ASCT) or
    2. Myeloma patients with prior relapse undergoing first ASCT. or
    3. Myeloma patients with relapsed disease after first ASCT who are undergoing second ASCT. Subjects must have achieved at least a partial response (PR) prior to proceeding to ASCT.
  2. Subject is > 18 and ≤ 70 years of age at the time of signing the informed consent form (ICF).
  3. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
  4. Subject is willing and able to adhere to the study schedule and other protocol requirements.
  5. Performance status of Karnofsky performance status ≥ 70% or Eastern Cooperative Oncology Group (ECOG) < 2
  6. Ability to be off immunosuppressive drugs for at least 3 days prior to the PNK-007 cell infusion. Steroids at the equivalent of no more than 5 mg prednisone per day are permissible.
  7. Be a candidate for ASCT based on institutional practices.
  8. Subjects must have autologous peripheral blood stem cell graft available in storage for additional transplant in the event of engraftment failure.
  9. Female of childbearing potential (FCBP) must:

    1. Have two negative pregnancy tests as verified by the Investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after the end of study treatment. This applies even if the subject practices true abstinence* from heterosexual contact.
    2. Either commit to true abstinence* from heterosexual contact (which must be reviewed at applicable study visits and source documented) or agree to use, and be able to comply with, effective contraception without interruption, during the study therapy (including dose interruptions), and for 28 days after discontinuation of PNK-007.

      A female of childbearing potential (FCBP) is a female who:

      1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months).

  10. Male subjects must:

    1. Practice true abstinence* (which must be reviewed at applicable study visits) or agree to use a condom during sexual contact while participating in the study, during dose interruptions and for at least 28 days following PNK-007 discontinuation, even if he has undergone a successful vasectomy. * True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, post ovulation methods] and withdrawal are not acceptable methods of contraception]).

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  1. Subject has plasma cell leukemia.
  2. Subject has non-secretory myeloma.
  3. Subject has previously undergone allogeneic stem cell transplant.
  4. Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
  5. Subject has any condition including the presence of laboratory abnormalities which places the subject at unacceptable risk if he or she were to participate in the study.
  6. Subject has any condition that confounds the ability to interpret data from the study.
  7. Subject has a body weight exceeding 120 kg.
  8. Subject has aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase ≥ 2.5 x the upper limit of normal (ULN) at screening.
  9. Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 at screening calculated using the Modification of Diet in Renal Disease Study equation.
  10. Subject has a bilirubin level > 2 mg/dL (unless subject has known Gilbert's disease) at screening.
  11. Subject has had prior treatment with biologic antineoplastic agents no less than 7 days before PNK-007 infusion and at least 5 half-lives. For agents that have known AEs occurring beyond 7 days after administration (ie, monoclonal antibodies), this period must be extended beyond the time during which acute AEs are known to occur.
  12. Subject is pregnant or breastfeeding.
  13. Subject has new or progressive pulmonary infiltrates or pleural effusion large enough to be detected by chest x-ray or computed tomography (CT) scan.
  14. Subject has active autoimmune disease other than controlled connective tissue disorder or those who are not on active therapy.
  15. Subject has human immunodeficiency virus (HIV) are excluded due to increased risk of lethal infections when treated with myeloablative chemotherapy.
  16. Subject has history of malignancy, other than multiple myeloma (MM), unless the subject has been free of disease for > 3 years from the date of signing the ICF. Exceptions include the following:

    1. Basal cell carcinoma of the skin
    2. Squamous cell carcinoma of the skin
    3. Carcinoma in situ of the cervix
    4. Carcinoma in situ of the breast
    5. Incidental histological finding of prostate cancer (TNM stage of T1a or T1b)
  17. Subject has a history of severe asthma and is presently on chronic medications or has a history of other symptomatic pulmonary disease.
  18. Untreated chronic infection or treatment of any infection with systemic antibiotics within 2 weeks prior to melphalan.
  19. Subject has any other organ dysfunction that will interfere with the administration of the therapy according to this protocol.
  20. Subject has a resting left ventricular ejection fraction (LVEF) of < 35% obtained by echocardiography or multigated acquisition scan (MUGA).
  21. Subject was treated with an investigational product no less than 28 days before PNK-007 infusion. Subject must no longer be a participant in the previous interventional study at the time of the PNK-007 infusion.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02955550


Contacts
Contact: Daniel Aversa 908.499.9666 daversa@Celgene.com
Contact: Catherine Balint, Clinical Research Scientist 732.564.3538 cbalint@celgene.com

Locations
United States, Minnesota
University of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55455
United States, Missouri
Washington Univ School of Medicine Siteman Cancer Center Recruiting
Saint Louis, Missouri, United States, 63110
United States, Nebraska
University of Nebraska Medical Center Recruiting
Omaha, Nebraska, United States, 68198-6805
United States, New Jersey
Hackensack University Medical Center Recruiting
Hackensack, New Jersey, United States, 07601
United States, New York
Roswell Park Cancer Institute Recruiting
Buffalo, New York, United States, 14263
Mt. Sinai School of Medicine Recruiting
New York, New York, United States, 10029
United States, Wisconsin
Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
Celgene
Investigators
Study Director: Mohamad Hussein, MD Celgene
  More Information

Responsible Party: Celgene
ClinicalTrials.gov Identifier: NCT02955550     History of Changes
Other Study ID Numbers: CCT-PNK-007-MM-001
First Submitted: November 2, 2016
First Posted: November 4, 2016
Last Update Posted: July 24, 2017
Last Verified: July 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Celgene:
Multiple Myeloma
Plasma Cell Myeloma
Plasma Cell Neoplasm
Relapsed/refractory Myeloma
PNK-007
Recombinant Human IL-2 (RHIL-2)
Human IL-2
Bone Marrow Transplant

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Aldesleukin
Interleukin-2
Antineoplastic Agents
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents